Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

[1]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[2]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[3]  R. Siliciano,et al.  Viral Dynamics in HIV-1 Infection , 1998, Cell.

[4]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[5]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[6]  ศิริลักษณ์ อนนันต์ณัฐศิริ,et al.  Antiretroviral Therapy for HIV Infection in 1998 , 1998 .

[7]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[8]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[9]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Yang,et al.  Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy , 1997, Nature Medicine.

[11]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[12]  M. Kreft,et al.  The effect of epidermal growth factor and transforming growth factor beta 1 on proliferation and differentiation of urothelial cells in urinary bladder explant culture. , 1997, Biology of the cell.

[13]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[15]  D. Kuritzkes,et al.  Human immunodeficiency virus type 1 protease inhibitors. , 1997, Archives of internal medicine.

[16]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[17]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[18]  B. Zinman,et al.  Insulin Lispro in CSII: Results of a Double-Blind Crossover Study , 1997, Diabetes.

[19]  S. Yerly,et al.  Detection of low HIV-1 RNA levels in plasma. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  M A Nowak,et al.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.

[21]  J. Kahn,et al.  HIV-1 protease inhibitors. A review for clinicians. , 1997 .

[22]  P. Volberding,et al.  HIV-1 protease inhibitors , 1992 .

[23]  K. Guthrie,et al.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. , 1996, Biochemistry.

[24]  M A Nowak,et al.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[26]  D. Kuritzkes,et al.  Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .

[27]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[28]  T. Schacker,et al.  Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[29]  D. Bolognesi,et al.  A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion , 1995, Journal of virology.

[30]  B. Irvine,et al.  Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[31]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[32]  D. Ho,et al.  Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. , 1995, AIDS research and human retroviruses.

[33]  T. Matthews,et al.  The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. , 1995, AIDS research and human retroviruses.

[34]  D. Richman,et al.  Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[35]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[36]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[37]  T. Oas,et al.  Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[40]  D. Bolognesi,et al.  Structural Rearrangements in the Transmembrane Glycoprotein after Receptor Binding , 1994, Immunological reviews.

[41]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[42]  T. Oas,et al.  A Peptide Inhibitor of Hiv-1 Replication: Correlation Between Solution Structure and Viral Inhibition , 1993 .

[43]  D. Richman.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents , 1993, Antimicrobial Agents and Chemotherapy.

[44]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[45]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Saag.  Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects. , 1992, Hospital practice.

[47]  E. Hunter,et al.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity , 1992, Journal of virology.

[48]  R. Chaisson,et al.  Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection , 1991, Antimicrobial Agents and Chemotherapy.

[49]  E. Delwart,et al.  Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. , 1990, AIDS research and human retroviruses.

[50]  R. Schooley,et al.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. , 1990, Annals of internal medicine.

[51]  R. Garry,et al.  A general model for the transmembrane proteins of HIV and other retroviruses. , 1989, AIDS research and human retroviruses.

[52]  J Desmyter,et al.  Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Mitsuya,et al.  Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. , 1988, Science.

[54]  B. Walker,et al.  HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.